Patents Assigned to Hookipa Biotech GmbH
  • Patent number: 11554169
    Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: January 17, 2023
    Assignee: Hookipa Biotech GmbH
    Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
  • Publication number: 20220289797
    Abstract: The present application relates to Pichinde viruses with rearrangements of their open reading frames (“ORF”) in their genomes. In particular. described herein is a modified Pichinde virus genomic segment, wherein the Pichinde virus genomic segment is engineered to carry a viral ORF in a position other than the wild-type position of the ORF. Also described herein are trisegmented Pichinde virus particles comprising one L segment and two S segments or two L segments and one S segment. The Pichinde virus, described herein may be suitable for vaccines md/or treatment of diseases and/or for the use in immunotherapies.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 15, 2022
    Applicants: Hookipa Biotech GmbH, Universität Basel
    Inventors: Weldi Bonilla, Daniel David Pinschewer, Klaus Orlinger
  • Publication number: 20220257734
    Abstract: The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for vaccines and/or treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with an immune checkpoint inhibitor, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.
    Type: Application
    Filed: January 24, 2022
    Publication date: August 18, 2022
    Applicant: Hookipa Biotech GmbH
    Inventors: Sarah Schmidt, Klaus Orlinger, Katherine Cohen
  • Patent number: 11407790
    Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: August 9, 2022
    Assignee: HOOKIPA BIOTECH GMBH
    Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
  • Patent number: 11266727
    Abstract: The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for vaccines and/or treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with an immune checkpoint inhibitor, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: March 8, 2022
    Assignee: Hookipa Biotech GmbH
    Inventors: Sarah Schmidt, Klaus Orlinger, Katherine Cohen
  • Patent number: 11214598
    Abstract: The present application provides immunotherapies for Hepatitis B virus infections. Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of Hepatitis B virus infections. Also provided herein are pharmaceutical compositions and methods for the treatment of Hepatitis B virus infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating Hepatitis B virus infection.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: January 4, 2022
    Assignee: Hookipa Biotech GmbH
    Inventors: Thomas Monath, Katherine Cohen, Vera Baumgartl-Strasser
  • Patent number: 10669315
    Abstract: Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: June 2, 2020
    Assignee: Hookipa Biotech GmbH
    Inventors: Klaus Orlinger, Thomas Monath, Anders Lilja, Sarah Schmidt, Ursula Berka, Michael Schwendinger, Elizabeth Watson, Bettina Kiefmann, Julia Hinteramskogler, Gerhard Fuhrmann, Andreas Aspöck, Katherine Cohen
  • Patent number: 10111945
    Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: October 30, 2018
    Assignee: Hookipa Biotech GmbH
    Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher